Themen – Stellungnahme zum Nutzenbewertungsverfahren zum Wirkstoff Vedolizumab (Neues Anwendungsgebiet: Antibiotika-refraktäre Pouchitis, vorbehandelte Patient*innen)

• Literatur

• 1 Shen B, Kochhar GS, Rubin DT. et al. Treatment of pouchitis, Crohnʼs disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol 2022; 7: 69-95
• 2 Gionchetti P, Rizzello F, Poggioli G. et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25: 1231-1236
• 3 Sambuelli A, Boerr L, Negreira S. et al. Budesonide enema in pouchitis – a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16: 27-34
• 4 Fang S, Kraft CS, Dhere T. et al. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016; 31: 1093-1094
• 5 Kelly OB, Rosenberg M, Tyler AD. et al. Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis. J Crohns Colitis 2016; 10: 410-417
• 6 Li Y, Lopez R, Queener E. et al. Adalimumab therapy in Crohnʼs disease of the ileal pouch. Inflamm Bowel Dis 2012; 18: 2232-2239
• 7 Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J. et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24: 756-758
• 8 Tran-Minh ML, Allez M, Gornet JM. Successful Treatment With Ustekinumab for Chronic Refractory Pouchitis. J Crohns Colitis 2017; 11: 1156
• 9 Winter TA, Dalton HR, Merrett MN. et al. Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis”. Scand J Gastroenterol 1993; 28: 701-704
• 10 Kucharzik T, Dignass AU, Atreya R. et al. Z Gastroenterol 2020; 58: e241-e326
• 11 Travis S, Silverberg M, Danese S. et al. Efficacy and Safety of Intravenous Vedolizumab for treatment of chronic Pouchitis: Results of the Phase 4 EARNEST trial. ECCO; P0448. 2022
• 12 Segal JP, Ding NS, Worley G. et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther 2017; 45: 581-592
• 13 Huguet M, Pereira B, Goutte M. et al. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohnʼs Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. Inflamm Bowel Dis 2018; 24: 261-268
• 14 Verstockt B, Claeys C, De Hertogh G. et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single- centre experience. United European Gastroenterol J 2019; 7: 1215-1225
• 15 Heuschen UA, Autschbach F, Allemeyer EH. et al. Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 2001; 44: 487-499
• 16 Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb 2001; 46: 334-337
• 17 Kayal M, Dubinsky MC. Medical management of chronic pouch inflammation. Curr Res Pharmacol Drug Discov 2022; 3: 100095
• 18 Shen B. Acute and chronic pouchitis--pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 323-333